Abstract
Background-Since 1989 long term oxygen therapy (LTOT) in Scotland has been prescribable only by respiratory physicians, whereas in England and Wales general practitioners can also prescribe this treatment. The effect of this policy has been audited.
Method -Six hundred and thirty patients were prescribed LTOT in Scotland be- tween poor compliance and 14 because the patient no longer met the criteria for LTOT.
Complete information was obtained from 519 case notes. In a few of the remaining 111 cases the information in the case notes was inadequate for our purposes, but the majority were not sent to us. There was no particular health board bias in this. Thus, a representative group of patients was assessed.
The SHHD guidelines are shown in table 1. In 79% of patients the diagnosis was COPD and, of the remaining 21%, 13% had pulmonary fibrosis and only 1% were paediatric cases. Our findings relate to all diagnoses (table  2) . Mean (SD) concentrator use was 14 9 (6 0) hours daily and ranged from one to 24 hours (figure). The concentrator was used by 44% of patients for <15 hours each day. Sixty one percent of patients were assessed when clinically unstable, as defined above, and 33% were assessed as an inpatient at the end of an exacerbation. Oedema was present at the time of assessment in 36% of cases who were also therefore clinically unstable by definition. In only 6% of cases were measurements of spirometric parameters and arterial blood gases repeated with an interval of at least three weeks as stated in the guidelines. Fourteen percent of patients were current smokers at prescription.
In those patients with COPD only 14% fitted all of the relative criteria for the prescription of LTOT if repeated measurements of arterial blood gas values and spirometric parameters three or more weeks apart are disregarded. In 2% the forced expiratory volume in one second (FEVI) was . 1-51 and in 22% it was not As expected, most patients prescribed LTOT had a diagnosis of COPD (79%). Mean compliance in our study was similar to that found in previous studies at 15 hours daily.45 Compliance ranged widely with only 56% ofpatients using their concentrator for 15 or more hours daily. Walshaw and coworkers found that less oxygen was prescribed on the advice of a general practitioner (10-6 hours daily) than either a non-respiratory physician (14 2 hours) or a respiratory physician (13-5 hours),6 and that 62% of patients prescribed LTOT by a respiratory physician used their concentrator for at least 15 hours daily while only 38% of those prescribed by a general practitioner did so.'
Thus it does appear that compliance is better, although still rather poor, in patients prescribed LTOT by respiratory physicians.
The most obvious problem related to compliance with the guidelines was that 61% of patients were prescribed LTOT when clinically unstable, usually while an inpatient at the end of an exacerbation. It is also of concern that 22% and 15%, respectively, of patients with COPD were prescribed LTOT without evidence of either FEV, or Pao2 having been measured.
In our study 14% of patients were still smoking when prescribed LTOT, in breach of the guidelines. There is obvious concern over safety as well as uncertainty as to the likely benefit of LTOT in patients who continue to smoke. In two other studies 19% and 20% of patients continued to smoke at prescription. 45 Thus, there is still considerable room for improvement in compliance and adherence to the guidelines even when LTOT is prescribed by respiratory physicians. Almost all patients in our study were followed up in a respiratory clinic where continuing patient education and encouragement can be given. Regular follow up at least twice yearly by a respiratory consultant is now recommended by the British Thoracic Society.7 The guidelines state that the aim of LTOT is to increase the Pao2 to 8 kPa or more without excessive hypercapnia. However, at prescription only 59% of patients had arterial blood gas tensions measured breathing oxygen, with 45% demonstrating satisfactory oxygenation. It is also important to ensure that patients continue to fulfil the criteria, but only 56% had further arterial blood gas measurements during the following two years -again less than half when clinically stable. This is particularly relevant as most patients are assessed for LTOT when clinically unstable and thus the Pao2 may continue to improve for up to three months following an exacerbation.8 Any patients who are prescribed domiciliary oxygen at the end of an exacerbation should be reviewed six weeks and three months after prescription when blood gas tensions on air should be measured to ensure that they still require LTOT. Ideally, LTOT should not be prescribed until patients are reviewed as outpatients when stable. Home checks of pulse or ear oximetry are recommended annually to confirm that the prescription remains appropriate and effective. 7 The number of deaths after prescription and the age of the patients suggests that LTOT is being prescribed late in the course of the disease. In our study 31 % were over the age of 70. Reluctance to prescribe earlier may relate to the lack of alternative modes of delivery tailored to different patient needs. Liquid oxygen was available during the MRC trial and is still available in the US and in Continental Europe. It is preferred to gaseous oxygen, allowing more mobile patients clear benefit with portable oxygen.9 Although liquid oxygen is more expensive it may encourage treatment earlier in the course of the disease; compliance may also increase, leading to improved survival. This study was supported by the Scottish Home and Health Department and the British Lung Foudation.
